531 related articles for article (PubMed ID: 28122627)
1. Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.
Moors TE; Hoozemans JJ; Ingrassia A; Beccari T; Parnetti L; Chartier-Harlin MC; van de Berg WD
Mol Neurodegener; 2017 Jan; 12(1):11. PubMed ID: 28122627
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy-Lysosome Pathway: A Systematic Review.
Wang ZY; Liu JY; Yang CB; Malampati S; Huang YY; Li MX; Li M; Song JX
Phytother Res; 2017 Aug; 31(8):1119-1127. PubMed ID: 28504367
[TBL] [Abstract][Full Text] [Related]
3. High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity.
Guttuso T
Med Hypotheses; 2019 Oct; 131():109302. PubMed ID: 31443765
[TBL] [Abstract][Full Text] [Related]
4. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
Bellomo G; Paciotti S; Gatticchi L; Parnetti L
Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779
[TBL] [Abstract][Full Text] [Related]
5. Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.
Zhang K; Zhu S; Li J; Jiang T; Feng L; Pei J; Wang G; Ouyang L; Liu B
Acta Pharm Sin B; 2021 Oct; 11(10):3015-3034. PubMed ID: 34729301
[TBL] [Abstract][Full Text] [Related]
6. Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics.
Senkevich K; Gan-Or Z
Parkinsonism Relat Disord; 2020 Apr; 73():60-71. PubMed ID: 31761667
[TBL] [Abstract][Full Text] [Related]
7. A Cleaning Crew: The Pursuit of Autophagy in Parkinson's Disease.
Parekh P; Sharma N; Gadepalli A; Shahane A; Sharma M; Khairnar A
ACS Chem Neurosci; 2019 Sep; 10(9):3914-3926. PubMed ID: 31385687
[TBL] [Abstract][Full Text] [Related]
8. Autophagy and Parkinson's Disease.
Lu J; Wu M; Yue Z
Adv Exp Med Biol; 2020; 1207():21-51. PubMed ID: 32671737
[TBL] [Abstract][Full Text] [Related]
9. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M; Brekk OR; Stefanis L
Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease.
Kinghorn KJ; Asghari AM; Castillo-Quan JI
Neural Regen Res; 2017 Mar; 12(3):380-384. PubMed ID: 28469644
[TBL] [Abstract][Full Text] [Related]
11. Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease.
Lastres-Becker I; García-Yagüe AJ; Scannevin RH; Casarejos MJ; Kügler S; Rábano A; Cuadrado A
Antioxid Redox Signal; 2016 Jul; 25(2):61-77. PubMed ID: 27009601
[TBL] [Abstract][Full Text] [Related]
12. The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective.
Martini-Stoica H; Xu Y; Ballabio A; Zheng H
Trends Neurosci; 2016 Apr; 39(4):221-234. PubMed ID: 26968346
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of mTORC1-TFEB axis in human iPSC model of
Mubariz F; Saadin A; Lingenfelter N; Sarkar C; Banerjee A; Lipinski MM; Awad O
Front Neurosci; 2023; 17():1152503. PubMed ID: 37332877
[TBL] [Abstract][Full Text] [Related]
14. Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson's models via regulating autophagy-lysosome pathway.
Xu J; Ao YL; Huang C; Song X; Zhang G; Cui W; Wang Y; Zhang XQ; Zhang Z
NPJ Parkinsons Dis; 2022 Aug; 8(1):100. PubMed ID: 35933473
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Gu XS; Wang F; Zhang CY; Mao CJ; Yang J; Yang YP; Liu S; Hu LF; Liu CF
Neurochem Res; 2016 Nov; 41(11):2923-2936. PubMed ID: 27447883
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
Moors T; Paciotti S; Chiasserini D; Calabresi P; Parnetti L; Beccari T; van de Berg WD
Mov Disord; 2016 Jun; 31(6):791-801. PubMed ID: 26923732
[TBL] [Abstract][Full Text] [Related]
17. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
18. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.
Pan T; Kondo S; Le W; Jankovic J
Brain; 2008 Aug; 131(Pt 8):1969-78. PubMed ID: 18187492
[TBL] [Abstract][Full Text] [Related]
19. A Self-Assembled α-Synuclein Nanoscavenger for Parkinson's Disease.
Liu J; Liu C; Zhang J; Zhang Y; Liu K; Song JX; Sreenivasmurthy SG; Wang Z; Shi Y; Chu C; Zhang Y; Wu C; Deng X; Liu X; Song J; Zhuang R; Huang S; Zhang P; Li M; Wen L; Zhang YW; Liu G
ACS Nano; 2020 Feb; 14(2):1533-1549. PubMed ID: 32027482
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of α-mangostin on mitochondrial dysfunction and α-synuclein aggregation in rotenone-induced model of Parkinson's disease in differentiated SH-SY5Y cells.
Hao XM; Li LD; Duan CL; Li YJ
J Asian Nat Prod Res; 2017 Aug; 19(8):833-845. PubMed ID: 28696167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
